Dexmedetomidine

SKU: orb1305360

Description

Dexmedetomidine

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 113775-47-6
• MW: 200.28
• Purity: 99.96%
• Formula: C₁₃H₁₆N₂
• SMILES: [C@H](C)(C1=C(C)C(C)=CC=C1)C2=CN=CN2
• Target: Adrenergic Receptor
• Solubility: DMSO:40 mg/mL (199.72 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (9.99 mM)

Bioactivity

• Target IC50:
  α2-adrenoceptor:1.08 nM(Ki )
• In Vitro:
  Dexmedetomidine has a relatively high ratio of α2/α1-activity (1620:1 as compared with 220:1 for clonidine) and, therefore, is considered a full agonist of the α2 receptor. This may result in more potent effects of sedation without unwanted cardiovascular effects from α1 receptor activation. The 2-h half-life of dexmedetomidine is nearly 4-fold shorter than that of clonidine, which increases the likelihood that a continuous infusion of dexmedetomidine might be useful for sedation. Dexmedetomidine also has minimum alveolar anesthetic concentration (MAC)-sparing properties, but its use as an anesthetic adjuvant has been complicated by persistent hypotension that has mandated IV fluid administration and vasopressor administration. In addition, its use in large doses is complicated by hypertension from α2 receptor-mediated vascular constriction.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

(+)-Medetomidine, (S)-Medetomidine, Adrenergic Receptor, adrenoceptor, AdrenergicReceptor, analgesia, anxiolysis, Beta Receptor, Dexmedetomidine, Inhibitor, inhibit, sedation, α2 receptor

Compound Identifiers

PubChem CID

5311068